CubeSmart vs GeneDx Holdings Corp — how do they compare? CubeSmart trades at $37.56 (market cap $8.38B), while GeneDx Holdings Corp trades at $67.73 (market cap $2.04B). The key difference: CubeSmart is far larger — about 4.1× GeneDx Holdings Corp's market cap, and CubeSmart pays a 5.69% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and GeneDx Holdings Corp for 19 Days on average.
| CUBE | WGS | |
|---|---|---|
Market Cap | $8.38B | $2.04B |
Volume | 2,231,307 | 659,215 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $167.51 |
52-Week Low | $35.36 | $34.51 |
Typical Hold Time | 89 Days | 19 Days |
Enterprise Value | $11.91B | $2.08B |
Dividend Yield | 5.69% | — |
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.51, down 0.66% on the day, with a bearish technical signal but improving operational trends. The REIT reported Q2 2026 earnings beats and raised full-year guidance, though funds from operations slightly missed estimates. Valuation ratios like P/E of 25.33 and P/S of 7.48 are elevated, while profitability remains solid with a 29.41% net income margin. Recent news highlights institutional buying and debates on REIT valuations amid AI sector shifts.
Outlook is mixed: analyst consensus targets $44.00 with a 'Buy' lean, but technicals and macroeconomic headwinds pose risks. The stock offers a 5.4% dividend yield, yet same-store NOI declines and high debt levels warrant caution. Upside depends on sustained occupancy gains and moderating supply pressures in the self-storage sector.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →